Sol-Gel Technologies宣告Sgt-610治疗戈林综合征的关键性III期临床试验迎来最后一位患者完成末次访视

美股速递
Sep 17

Sol-Gel Technologies宣布,其针对Sgt-610在戈林综合征治疗中的关键性III期临床试验,已顺利完成最后一位患者的末次访视。这一里程碑式的进展,标志着该试验的核心临床阶段正式落下帷幕。公司表示,此举为后续的数据分析及潜在监管提交铺平了道路,有望为这一罕见遗传病患者群体带来新的治疗曙光。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10